Cargando…

Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant?

We present the case of an HIV-negative man in his 50s who developed a generalised nodular rash while having first-line bortezomib–cyclophosphamide–dexamethasone chemotherapy for multiple myeloma. The rash was biopsied and proven to be Kaposi’s sarcoma. The patient’s treatment was interrupted at the...

Descripción completa

Detalles Bibliográficos
Autores principales: Farrugia, Daniel, Sultana, Erika, Babic, Darko, Grech, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255255/
https://www.ncbi.nlm.nih.gov/pubmed/37263679
http://dx.doi.org/10.1136/bcr-2022-251044
_version_ 1785056827289894912
author Farrugia, Daniel
Sultana, Erika
Babic, Darko
Grech, Mark
author_facet Farrugia, Daniel
Sultana, Erika
Babic, Darko
Grech, Mark
author_sort Farrugia, Daniel
collection PubMed
description We present the case of an HIV-negative man in his 50s who developed a generalised nodular rash while having first-line bortezomib–cyclophosphamide–dexamethasone chemotherapy for multiple myeloma. The rash was biopsied and proven to be Kaposi’s sarcoma. The patient’s treatment was interrupted at the sixth cycle of chemotherapy, by which time the rash had also spread to the oral mucosa and eyelid. The rash regressed spontaneously on stopping treatment. We were reluctant to restart myeloma treatment, but on the other hand, we wished to consolidate the very good partial response achieved. An autologous marrow transplant was done months later without any recurrence of his Kaposi’s with the initiation of bortezomib maintenance. Bortezomib has putative activity against Kaposi’s. The patient could benefit from imid-based (thalidomide, lenalidomide, pomalidomide) combination chemotherapy once his myeloma progresses or if there is a recurrence of Kaposi’s sarcoma.
format Online
Article
Text
id pubmed-10255255
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-102552552023-06-10 Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant? Farrugia, Daniel Sultana, Erika Babic, Darko Grech, Mark BMJ Case Rep Case Reports: Adverse drug reactions and complications We present the case of an HIV-negative man in his 50s who developed a generalised nodular rash while having first-line bortezomib–cyclophosphamide–dexamethasone chemotherapy for multiple myeloma. The rash was biopsied and proven to be Kaposi’s sarcoma. The patient’s treatment was interrupted at the sixth cycle of chemotherapy, by which time the rash had also spread to the oral mucosa and eyelid. The rash regressed spontaneously on stopping treatment. We were reluctant to restart myeloma treatment, but on the other hand, we wished to consolidate the very good partial response achieved. An autologous marrow transplant was done months later without any recurrence of his Kaposi’s with the initiation of bortezomib maintenance. Bortezomib has putative activity against Kaposi’s. The patient could benefit from imid-based (thalidomide, lenalidomide, pomalidomide) combination chemotherapy once his myeloma progresses or if there is a recurrence of Kaposi’s sarcoma. BMJ Publishing Group 2023-06-01 /pmc/articles/PMC10255255/ /pubmed/37263679 http://dx.doi.org/10.1136/bcr-2022-251044 Text en © BMJ Publishing Group Limited 2023. No commercial re-use. See rights and permissions. Published by BMJ.
spellingShingle Case Reports: Adverse drug reactions and complications
Farrugia, Daniel
Sultana, Erika
Babic, Darko
Grech, Mark
Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant?
title Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant?
title_full Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant?
title_fullStr Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant?
title_full_unstemmed Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant?
title_short Iatrogenic Kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant?
title_sort iatrogenic kaposi’s sarcoma from induction therapy for myeloma: to transplant or not to transplant?
topic Case Reports: Adverse drug reactions and complications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10255255/
https://www.ncbi.nlm.nih.gov/pubmed/37263679
http://dx.doi.org/10.1136/bcr-2022-251044
work_keys_str_mv AT farrugiadaniel iatrogenickaposissarcomafrominductiontherapyformyelomatotransplantornottotransplant
AT sultanaerika iatrogenickaposissarcomafrominductiontherapyformyelomatotransplantornottotransplant
AT babicdarko iatrogenickaposissarcomafrominductiontherapyformyelomatotransplantornottotransplant
AT grechmark iatrogenickaposissarcomafrominductiontherapyformyelomatotransplantornottotransplant